No drug has been approved to treat tinnitus as of 2026. The new treatments in testing are early: a cochlear synaptopathy drug and anti-CGRP migraine drugs in registered trials, deep brain stimulation in four people, and better ways to combine the treatments that already exist.
The medications covered elsewhere, such as melatonin and antidepressants used off-label, treat related problems like sleep or mood rather than tinnitus as an approved indication. A 2022 review written by developers of one tinnitus drug candidate puts it flatly: no therapeutics for any auditory-related indication have been FDA approved.
Drug candidates in trials
Targeting cochlear synaptopathy. Cilcare's CIL001, the compound paliroden, targets cochlear synaptopathy: damage to the connection between the cochlea's hair cells and the auditory nerve, a mechanism implicated in tinnitus and in difficulty following speech in noise even when standard hearing tests look normal. The company announced a US trial with Massachusetts General Hospital in May 2026. Its registry entry describes a randomised, double-blind, placebo-controlled phase 1b/2a trial of a single injection through the eardrum, in about 60 adults with normal hearing thresholds, constant tinnitus in both ears and difficulty hearing speech in noise. Its primary outcome is safety over six months. It was registered in September 2026, not yet recruiting, with a planned start in January 2027.
Repurposed migraine medications. Tinnitus often occurs alongside migraine, and some researchers think the two share mechanisms. A 2025 placebo-controlled trial at UC Irvine gave 78 people with moderate to severe tinnitus nortriptyline with topiramate, verapamil with paroxetine, or a placebo for eight weeks, choosing the combinations for their migraine-preventing effects. Both drug groups improved against their own starting scores, but the difference between the arms was not significant (p = .265). The patterns that make a weak tinnitus result look strong uses it as its first example.
The next step is the newer migraine drugs that block CGRP, a protein involved in migraine. A Stanford trial registered in 2026, COMPACT-PM, plans to compare anti-CGRP therapies with conventional migraine preventives in about 120 adults with bothersome tinnitus and a history of migraine, measuring change on the Tinnitus Functional Index over 24 weeks. Both groups receive active treatment and there is no placebo arm, so it can show which class does better, not how either compares with nothing. When it was registered in June 2026 it was not yet recruiting.
The candidates that have already reported are a separate and more sobering story. What happened to the tinnitus drugs you read about follows AM-101, OTO-313 and SPI-1005 through their trials. Every compound developed specifically for tinnitus that has reported a controlled phase 2 result has failed its primary endpoint, and one was defeated by an unexpectedly strong placebo response in a trial designed to prevent exactly that.
Combining treatments: UNITI has reported
One of the more practically significant research efforts is the UNITI trial, a large European study designed to test whether combining treatments produces better outcomes than any single one for chronic tinnitus. Treatment response varies widely between people, as covered in when treatments don't work, so this kind of study can matter as much for everyday care as a new drug.
It reported in 2025, in Nature Communications: 461 patients, ten treatment arms, twelve weeks. Combination treatment beat single treatment on the Tinnitus Handicap Inventory — 14.9 points against 11.7, p = 0.034 — and the mechanism was not the expected one. The trial found no synergy between treatments, and instead a compensatory effect in which a more effective treatment offsets a less effective one. CBT and hearing aids alone had large effect sizes that combining could not improve on. What UNITI found covers the result and why "combination is better" turns out to be a weaker claim than it sounds.
It is a good illustration of why this page exists. A study once listed here as promising has landed, and the answer it gave was more interesting than a yes.
What the field itself says it is working on
Rather than assembling a list from press releases, it is worth taking the one the field publishes about itself. The 2026 Nature Reviews Disease Primers volume on tinnitus, a review of the whole field written by ten researchers, names its new areas of research:
- Biomarkers — an objective measure of tinnitus, which the field still does not have. Covered under tinnitus biomarkers research.
- Deciphering tinnitus genetic architecture — see genetics and tinnitus.
- Inner ear regeneration — restoring the hair cells whose loss starts the process. Hair cell regeneration and gene therapy covers what has worked there, including the gene therapy trials that restored hearing in deaf children, and why they are not what most people are hoping for.
- Closed-loop neuromodulation — stimulation that adjusts itself in response to what the brain is doing, rather than running a fixed protocol.
- Digital therapeutics — app-delivered treatment, covered under tinnitus apps and internet-based CBT.
Two things are worth noticing about that list. Not one of them is a drug, in a field where drug announcements get the most coverage. And the two most mature entries, digital therapeutics and neuromodulation, are the ones that already have trial evidence attached, which is a reasonable guide to which of the rest will arrive first. The same review names counselling and cognitive behavioural therapy as first-line treatments.
Deep brain stimulation, at the earliest possible stage
The most invasive thing currently being tested is deep brain stimulation: implanted electrodes of the kind used in Parkinson's disease.
A 2026 feasibility study in Neurotherapeutics, from Maastricht University Medical Centre, implanted bilateral electrodes in the medial geniculate body — a relay station on the auditory pathway — in patients with treatment-refractory, severe, chronic tinnitus and no anatomical cause. The design was a randomised, double-blind 2 × 2 crossover, with patients assigned to stimulation ON-then-OFF or OFF-then-ON.
Four patients. That is the most important fact about the study, and the authors frame it accordingly: the primary outcomes were safety and feasibility, not effectiveness.
What they report: no irreversible stimulation-induced side effects, surgical side effects that were transient and resolved within two weeks, and all four patients describing DBS as an acceptable treatment. Three of the four improved on the Tinnitus Functional Index. In the one who did not, the electrodes sat furthest from the centre of the target.
That last detail is the intriguing one, because it is the shape you would expect if the effect were real — closer to target, better result. It is also a single non-responder out of four, which is equally consistent with chance.
This is not a treatment and should not be read as one. It is four people, in a study built to establish whether the procedure can be done safely enough to justify testing whether it works at all. The authors say precisely that: effectiveness needs evaluating in a follow-up study. What it demonstrates is that the question has become answerable, which it was not before.
CBT research continues to grow
Research volume on CBT for tinnitus has shown a steady upward trend over recent decades, with current work focused on refining who benefits most, comparing digital with in-person delivery, and identifying the characteristics of people who do not respond well to standard CBT. The aim is to match people to the right format rather than use one protocol for everyone.
What this means if you have tinnitus today
None of the drug candidates above is an available treatment, and it is uncertain which, if any, will complete trials and reach approval; early positive signals in small trials frequently do not hold up in larger ones. The realistic position is not to wait for a cure. Counselling and CBT, hearing aids and sound therapy are available now, and for some people bimodal neuromodulation, while research on new drugs and on better combinations of existing treatments continues. This page is updated as trials report.
For the wider research picture, see the state of tinnitus data for the compiled global figures, notable tinnitus studies for a dated log of the studies that have reported, and AI and machine learning in tinnitus care for where that technology stands. One further line of enquiry attracts more attention than its evidence supports: psychedelic research and tinnitus covers what is being studied, which is considerably less than the coverage suggests.